Resmetirom and semaglutide treat fatty liver through different mechanisms: energy expenditure vs appetite suppression | Research

The takeaway

In MC4R-KO MASH mice, resmetirom enhanced oxygen consumption while semaglutide reduced energy expenditure and lean mass; resmetirom improved steatosis scores while semaglutide better reduced fibrosis, revealing complementary mechanisms.

Complementary MASH mechanisms
Resmetirom increases metabolism → better steatosis; semaglutide suppresses appetite → better fibrosis. Combination may address all MASH components.

What the researchers found

Both: improved liver hydroxyproline, total fat. Resmetirom: ↑O2 consumption, significantly improved steatosis. Semaglutide: ↓energy expenditure, ↓lean mass, significantly reduced fibrosis. Different mechanisms confirmed. First head-to-head comparison.

Why it matters

With both drugs available for MASH, understanding their different mechanisms enables rational combination strategies. Resmetirom targets fat through metabolism; semaglutide targets fibrosis through weight/inflammation—together they could address all MASH components.

How the study worked

MC4R-KO mice on western diet. 6 weeks disease induction + 7 weeks drug treatment. Resmetirom vs semaglutide vs control. Body composition, metabolic cages, histopathology (steatosis + fibrosis scores).

What this study cannot tell us

Mouse model (MC4R-KO). Short treatment (7 weeks). Cannot directly translate doses to humans. Lean mass loss in mice may differ from humans.

How to read the evidence

First preclinical head-to-head comparison in a validated MASH model. Strong mechanistic evidence.

When this study was published

Published in 2025.

The bigger picture

This head-to-head comparison establishes that the two leading MASH drugs work through complementary mechanisms, providing the strongest rationale yet for combination therapy.

Questions still open

Would combining resmetirom + semaglutide improve both steatosis AND fibrosis?
Does semaglutide's lean mass reduction in mice reflect clinical muscle loss?
Should MASH patients receive one or both drugs based on their histological profile?

Common questions

Should I take resmetirom or semaglutide for fatty liver?

This study suggests they work differently: resmetirom is better for fat buildup (steatosis) by increasing metabolism, while semaglutide is better for scarring (fibrosis) by reducing appetite and inflammation. Combination therapy may be best for comprehensive MASH treatment.

Does semaglutide cause muscle loss in MASH?

In this mouse study, semaglutide reduced lean mass along with fat—consistent with clinical concerns about muscle loss. Resmetirom did not have this effect. This supports monitoring muscle mass and ensuring adequate protein intake for MASH patients on semaglutide.

Read the original research

Differences between therapeutic mechanisms of resmetirom and semaglutide against MASH in western diet-fed MC4R-knockout mice.

Scientific reports, 15(1), 41068

View on PubMed ↗Publisher’s paper ↗

Citation

Sugawara, Takumi; Hitaka, Kosuke; Matsumoto, Mitsuharu; Nakamura, Sayuri; Kobayashi, Ryosuke; Kandori, Hitoshi; Nio, Yasunori. (2025). Differences between therapeutic mechanisms of resmetirom and semaglutide against MASH in western diet-fed MC4R-knockout mice.. Scientific reports, 15(1), 41068. https://doi.org/10.1038/s41598-025-24927-3